Citadel Advisors’s Health Catalyst HCAT Stock Holding History
Bought
Maintained
Sold
Other funds holding HCAT
CF
MBAM
Citadel Advisors's HCAT Position: Q3 2026 in Review
Citadel Advisors reduced its Health Catalyst (HCAT) stake by 53% in Q3 2026, selling an estimated $454K and leaving 215,206 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #10889.
Citadel Advisors first reported a position in HCAT in Q3 2019 and has held it in 25 quarters since. The position peaked at $12.4M in Q1 2022. 109 funds tracked by Wall St. Rank hold HCAT as of Q3 2026.
- Citadel Advisors held 215,206 shares of Health Catalyst worth $372K as of Q3 2026.
- Citadel Advisors sold 238,008 Health Catalyst shares in Q3 2026, an estimated $454K.
- Health Catalyst made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #10889 holding.
- Citadel Advisors first reported a position in Health Catalyst in Q3 2019 and has held it in 25 quarters since.
- Citadel Advisors's Health Catalyst position peaked at $12.4M in Q1 2022.
- 109 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.